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ABSTRACT 
Background: Quadriceps weakness is an important complication of advanced 
COPD but few data exist concerning muscle bulk in early disease. We hypothesised 
that quadriceps bulk, measured by ultrasound rectus femoris cross-sectional area 
(USRFCSA), would be reduced in mild as well as advanced COPD compared to 
controls and would correlate with physical activity. 
Methods: 161 patients with stable COPD and 40 healthy subjects had a 
measurement of USRFCSA and wore a multisensor armband to record physical 
activity.  
Results: USRFCSA was reduced in GOLD stage I patients compared to healthy 
subjects (p=0.0002). Stage II-IV patients had reduced USRFCSA (p<0.0001) 
compared to controls but were not significantly different from stage I disease. 
Physical activity level was reduced in stage I (p=0.002) and stage II-IV disease 
compared to controls. Using regression analysis, physical activity level was 
independently associated with USRFCSA in stage I (p=0.01), but not stage II-IV 
disease where residual volume to total lung capacity (RV/TLC) ratio was the only 
independent predictor of physical activity level. 
Conclusions: Quadriceps wasting exists in patients with mild, as well as advanced, 
COPD and is independently associated with physical inactivity in GOLD stage I 
disease. The identification of these patients may guide early lifestyle and therapeutic 
interventions. 
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INTRODUCTION 
Skeletal muscle dysfunction is a well recognised extrapulmonary complication of 
chronic obstructive pulmonary disease (COPD) with loss of lean body mass identified 
as a key determinant of disability [1] and an independent predictor of mortality [2]. In 
particular, reduced quadriceps strength is associated with reduced exercise capacity 
[3], impaired quality of life [4], increased healthcare use [5] and mortality independent 
of airflow obstruction [6].  
The mechanisms involved in the development of skeletal muscle weakness in COPD 
are likely to be multi-factorial with systemic factors, such as oxidative stress [7], 
thought to interact with the key local factor of muscle inactivity [8, 9] particularly in the 
lower limbs [10]. Objectively measured physical activity has been identified as a 
strong predictor of all-cause mortality in COPD [11], highlighting its importance in a  
‘downward disease spiral’ where progressive dyspnoea leads to reduced exercise 
capacity with subsequent muscle deconditioning and further inactivity [12].  
Quadriceps weakness has recently been observed in the absence of severe airflow 
obstruction in COPD [13], and in addition there is data to suggest a reduction in 
physical activity in GOLD stage I patients [14]. Despite the potential rationale for 
muscle wasting in mild disease, little data exists on reduced quadriceps bulk in this 
patient group. Mid-thigh cross-sectional area measured by computed tomography 
(CT) has been shown to predict mortality in moderate-severe COPD [15], however 
the ionising radiation exposure makes this method of imaging undesirable particularly 
in mild disease. Magnetic resonance imaging (MRI) has also been used as a thigh 
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muscle imaging modality in COPD [16] but the accessibility and expense of this tool 
prohibit its adoption in the wider COPD population.  
Ultrasound measurement of rectus femoris cross-sectional area (USRFCSA) is a 
radiation-free measure of muscle bulk that relates to quadriceps strength in COPD 
but is effort independent [17]. We hypothesised that quadriceps wasting, measured 
by USRFCSA, would be observed in mild as well as advanced COPD compared to 
healthy age-matched subjects and that this would correlate with daily physical activity 
levels. 
 
 
METHODS 
Patients and study design 
This cross-sectional study was approved by the Joint University College London 
Committees on the Ethics of Human Research (Committee Alpha) and the Ethics 
Committee of the Royal Brompton and Harefield NHS Foundation Trust. All 
participants provided written informed consent. The COPD patients were recruited 
through outpatient clinics at the Royal Brompton Hospital, King’s College and St 
Thomas’ Hospitals as well as through public events conducted on World COPD and 
No-Smoking days. The period of recruitment was from August 2009 to August 
2011. COPD patient diagnosis was based on NICE guidelines [18] with severity 
defined using GOLD stage classification. Subjects within one month of an 
exacerbation or with a significant co-morbidity including cardiac failure, neurological 
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disease or rheumatoid arthritis that limited muscle function or activity level were 
excluded. Healthy age-matched controls were recruited by advertisement in local 
newspapers. 
Ultrasound Rectus Femoris Cross-sectional area 
Measurement of quadriceps rectus femoris cross-sectional area was made by 
ultrasound using a technique previously described by Seymour et al [17]. B-mode 
ultrasonography was used with an 8MHz 7cm linear array transducer (PLF 805 ST, 
Toshiba Medical Systems, Crawley, UK). Two trained operators (DS and MP) 
performed the ultrasound examinations. The patient was positioned supine with the 
rested leg supported in passive extension. An anatomical landmark was found at 
three-fifths distance along a line from the anterior superior iliac spine to the superior 
patella border. The transducer was positioned in the transverse plane and orientated 
so that the entire rectus femoris cross-sectional area could be visualised onscreen. 
This image was frozen (figure 1) and the echogenic line representing the fascia 
around the rectus femoris was outlined manually by the operator. Rectus femoris 
cross-sectional area was calculated using a planimetric technique (Nemio, Toshiba 
Medical Systems) and the average of three consecutive measurements was taken.  
Quadriceps strength and fat-free mass measurements  
A volitional measurement of quadriceps maximum voluntary contraction (QMVC) was 
made using the technique described by Edwards et al 1977 [19]. Subjects sat on a 
modified chair with their knee fixed at 90° and performed at least 3 sustained 
maximal isometric quadriceps contractions. QMVC was taken as the highest tension 
sustained for 1 second. 
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Fat free mass index (FFMI)  was determined by bioelectrical impedance analysis at 
50kHz (BodyStat QuadScan 4000; BodyStat, Douglas, United Kingdom) and a 
disease specific regression equation [20]. Measurements of the impedance at 5kHz 
and 200kHz also allowed calculation of the bioelectrical impedance ratio (Z200/Z5).  
Health-related quality of life was determined using the St. George’s Respiratory 
Questionnaire (SGRQ) and breathlessness was recorded using the Medical 
Research Council (MRC) dyspnoea score. A detailed description of techniques has 
been included in the online supplement.                                   
Physical Activity Monitoring 
Daily physical activity was recorded using a multisensor biaxial accelerometer 
armband (SenseWear, BodyMedia; Pittsburgh, PA) as previously described by Watz 
et al [9]. The armband incorporates physiological sensors that quantify galvanic skin 
response, heat flux and skin temperature to estimate energy expenditure and has 
been previously validated against indirect calorimetry in COPD patients [21, 22] and 
against the doubly labelled water technique in healthy subjects [23]. The physical 
activity level (PAL) was calculated using total energy expenditure (TEE) and sleep 
energy expenditure as a surrogate for resting energy expenditure (REE) 
(PAL=TEE/REE). Daily step count and PAL were measured over six consecutive 
days incorporating one weekend and four weekdays. A valid physical activity 
assessment was defined as ≥21.5 hours (90%) wearing time a day on at least 5 
days. Data were downloaded and analysed using Sensewear professional software 
version 6.1. 
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Pulmonary Function Testing 
Pulmonary function testing was undertaken by the Royal Brompton Hospital Lung 
Function Department. Spirometry, plethysmographic lung volumes, carbon monoxide 
diffusing capacity (TLco) (CompactLab system; Jaeger, Wurzburg, Germany) and 
arterial blood gases were determined in accordance with European Respiratory 
Society (ERS) /American Thoracic Society (ATS) recommendations [24-26].   
Data and Statistical Analysis 
Data are presented as mean ± SD, with accompanying p value, and analysis was 
performed using StatView 5.0 (Abacus concepts, Inc., Berkeley, CA, USA). Between 
group comparisons used analysis of variance (ANOVA), with post-hoc correction for 
more than 2-groups. Relationships between USRFCSA, quadriceps strength, FFMI, 
impedance ratio, daily physical activity and pulmonary function were analysed using 
univariate and multivariate linear regression models. Figure construction was 
performed with GraphPad Prism Version 5.0 (GraphPad Software, San Diego, 
California, USA). 
 
RESULTS 
Two hundred and one subjects, comprising 161 stable COPD patients and 40 healthy 
age-matched volunteers, participated in the study.  Baseline characteristics are 
shown in table 1. Of these, 154 subjects (123 COPD patients and 31 healthy 
participants) completed a valid physical activity assessment. Out of the remaining 47 
subjects, 14 did not complete a valid period of assessment, 4 subjects declined to 
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participate in this part of the study and the remainder were not given an armband for 
logistical reasons (e.g. armband availability and subject’s distance from hospital). In 
those subjects participating in activity monitoring, a valid period of assessment was 
reached in 92% (154/168). Average wearing time per day was 98% and did not 
significantly differ across groups (see table 2).   
USRFCSA and quadriceps strength in COPD (Stage I-IV) and healthy subjects 
USRFCSA and quadriceps strength (QMVC) were reduced in all GOLD stages 
compared to controls (table 2, figure 2 and figure 3). There were no significant 
differences in USRFCSA or QMVC across GOLD stages, except between QMVC in 
stage I and IV (p<0.02). In COPD patients, FEV1% predicted showed no association 
with USRFCSA and a weak association with QMVC (r=0.2, p=0.03). USRFCSA had a 
linear relationship with QMVC in COPD subjects (r=0.6, p<0.0001) (online fig 1). 
QMVC was also significantly associated with FFMI (r=0.54, p<0.0001) and the 
impedance ratio (Z200/Z5) (r=−0.54, p<0.0001) in COPD (online fig 2). A multiple 
regression model was used to predict USRFCSA in all COPD subjects incorporating 
the significant independent variables from the univariate analysis (online table 1). 
Gender (r=0.27, p=0.003), QMVC (r=0.24, p=0.01), residual volume to total lung 
capacity (RV/TLC) ratio (r=−0.28, p=0.01), inspiratory capacity (IC) (r=0.20, p=0.04) 
and FFMI (r=0.19, p=0.04) were retained as independent predictors of USRFCSA 
(r=0.75, p<0.0001). In a similar multiple regression model with QMVC as the 
dependent variable, only USRFCSA (r=0.24, p=0.02) and FFMI (r=0.25, p=0.01) were 
retained as independent predictors of quadriceps strength in COPD (r=0.74, 
p<0.0001). As gender was identified as an independent variable to predict USRFCSA, 
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the COPD and healthy subjects were separated into males and females (online fig 3). 
In both genders, USRFCSA was reduced in all GOLD stages compared to controls and 
there were no significant differences in USRFCSA across GOLD stages. Males 
(n=108) had a significantly greater USRFCSA, compared to females (n=93), 597mm
2 
vs 470mm2, (p<0.0001).  
Relationship of daily physical activity with GOLD stage and USRFCSA  
Daily physical activity was significantly reduced in all GOLD stages compared to 
healthy controls (figure 4 and figure 5).  Mean group differences are shown in table 2. 
Daily physical activity showed a linear relationship with FEV1% predicted (steps, 
r=0.6; PAL, r=0.4, p<0.0001) and USRFCSA (steps, r=0.3, p=0.002; PAL, r=0.2 
p<0.05) in all COPD patients. In stage I disease, a multiple linear regression model to 
predict USRFCSA was used incorporating the significant independent variables from 
the univariate analysis (online table 2).  Physical activity level was the only variable 
retained as an independent predictor of USRFCSA in stage I disease (r=0.76, p=0.01). 
In a similar regression analysis in stage II-IV disease, gender (r=0.29, p=0.01), 
RV/TLC ratio (r=−0.28, p=0.01) and IC (r=0.29, p=0.02) but not physical activity, were 
retained as independent predictors of USRFCSA (r=0.78, p<0.0001).  
In a separate multiple linear regression model to predict physical activity in stages II-
IV COPD, when incorporating the univariate correlates (online table 3), RV/TLC ratio 
was retained over FEV1% predicted as the only independent variable associated with 
physical activity level (r=−0.23, p=0.03). Using this model in stage I COPD, USRFCSA 
but not QMVC was retained as the only independent correlate with physical activity 
level (r=0.64, p=0.005).  
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Ultrasound validity and reproducibility 
A subset of 80 COPD patients had an additional mid-thigh CT scan (detailed in online 
supplement) with ultrasound rectus femoris cross-sectional area correlating 
significantly with mid-thigh CTCSA (r=0.7, p<0.0001) and rectus femoris CTCSA (r=0.7, 
p<0.0001). Further data on inter-occasion and observer variability (online fig 4), 
ultrasound measurement of the pennation angle and use of different measurement 
points are described in the supplement (online table 4).  
 
 
DISCUSSION 
Using USRFCSA we found quadriceps wasting in mild, as well as advanced COPD 
judged by GOLD stage. A 17% reduction in mean USRFCSA was observed in stage I 
patients compared to a healthy age matched group with a similar whole-body FFMI. 
The study also identified an independent association between physical activity level 
and USRFCSA in stage I disease, with this group significantly less active when 
compared to healthy subjects. 
Significance of the findings 
A recent study incorporating a large UK and Dutch COPD cohort [13] identified a 
28% prevalence of quadriceps weakness in Stage I patients and supports our 
contention that reduced quadriceps muscle bulk is present in early disease. The 
simple and effort independent nature of ultrasound makes it an attractive test for 
detecting patients who may benefit from early intervention and avoids the need for 
strength measurements using research based equipment or less reliable portable 
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handheld devices, both of which are inherently subject to volitional influence.  
Interestingly, in our study, USRFCSA rather than quadriceps strength was 
independently associated with physical activity in stage I COPD, implying that this 
effort independent measure of quadriceps size may be a more sensitive parameter 
for investigating the relationship between lower limb muscle dysfunction and physical 
activity in patients with mild disease. This is particularly important as new COPD 
phenotypes are established requiring evaluation and as therapeutic interventions 
focus on physical activity promotion [27]. 
The finding of reduced daily physical activity in Stage I COPD compared to healthy 
subjects is supported by previous data from Watz et al [14] showing a reduction in 
activity in GOLD Stage I patients compared to a chronic bronchitis (formerly GOLD 
stage 0) cohort. Although their observed reduction did not reach statistical 
significance the comparison was not made with a healthy control group as in our 
current study. There have been very few other studies investigating physical activity 
in mild to moderate COPD patients.  A multi-centre study recently found a reduction 
in early disease from stage II COPD onwards compared to healthy controls, however 
this study had a small number of patients (n=9) with GOLD stage I disease [28]. 
There is evidence to suggest that symptomatic GOLD stage I patients experience 
dynamic hyperinflation associated with dyspnoea during exercise compared to 
control subjects [29]. GOLD stage I patients in our study had a significantly higher 
MRC dyspnoea score compared to healthy controls and this may therefore provide a 
mechanism for the initial reduction in physical activity seen early in the disease 
process. 
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The finding of reduced physical activity in stage I COPD and its association with 
USRFCSA allows discussion of a potential mechanism for reduced quadriceps bulk in 
mild disease. Stage II-IV patients also demonstrated a reduction in quadriceps bulk 
compared to control subjects but this was not significantly different from the stage I 
group suggesting that a threshold level of physical inactivity, reached early in the 
disease process, triggers the depletion in muscle bulk. There is evidence from the 
Copenhagen City Heart Study [30] and elsewhere [31] that physical inactivity may in 
fact precede the occurrence of airflow obstruction and that it is a significant 
aetiological factor for the development of COPD. In addition, recent data has 
highlighted physical activity to be a strong predictor of all-cause mortality in COPD 
[11] emphasising its importance in this patient group, although that study compared 
activity to measures of whole body FFM and BMI, rather than quadriceps muscle bulk 
or strength.  In keeping with previous work [14, 32], we found that lung function is 
associated with the level of physical activity in COPD, with RV/TLC ratio rather than 
FEV1% predicted found to be an independent predictor of physical activity level in 
stage II-IV disease. USRFCSA was also independently associated with RV/TLC ratio 
and IC, but not FEV1% predicted, highlighting that although FEV1 can be used for 
classifying the severity of airflow obstruction [33] it does not reflect the true severity 
of the disease. There is increasing evidence to support measures of gas trapping and 
thoracic distension as better indicators of disease severity than airflow obstruction in 
COPD [34, 35]. Our finding that USRFCSA has a stronger association with physical 
activity in the mild compared to more advanced group, suggests that these 
pulmonary factors are more limiting to activity in moderate-severe patients, compared 
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to those with mild COPD where the association between muscle wasting and 
inactivity is more pronounced.  
Importantly, in our study whole-body measurement of FFMI was similar in controls 
and patients with mild disease, although USRFCSA was reduced, supporting local 
disuse as a key factor. Disuse may also increase susceptibility to systemic factors, 
particularly the effects of smoking which is in itself known to be associated with 
skeletal muscle oxidative stress [36] and quadriceps weakness [37]. It should be 
noted however that inactivity may act as a significant confounder when observing 
quadriceps dysfunction as an effect of smoking. Further studies are needed to 
explore whether the fibre type switch from oxidative type I fibres to anaerobic type II 
fibres reported in advanced COPD [38], occurs earlier in the disease process as a 
consequence of physical inactivity interacting with systemic effects.  
Of additional note from this study, the bioelectrical impedance ratio (Z200/Z5) has 
been found to show strong associations with USRFCSA and quadriceps strength in 
COPD patients; univariate correlates are shown in the supplement (online table 5). At 
the low (5 kHz) frequency, current does not penetrate cell membranes however at 
the high (200 kHz) frequency, both intracellular and extracellular spaces are 
penetrated. Therefore, the ratio of the bioelectrical impedance at these frequencies 
(Z200/Z5) is thought to give an index of separation of the two compartments; 
extracellular and total body water. In contrast to the use of bioelectrical impedance 
analysis to calculate fat free mass using regression equations which may include 
height, weight and gender, the impedance ratio is based on direct measurements. 
The ratio may be influenced by acute or chronic illness with a higher value already 
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shown to be associated with greater disease severity in patients with heart failure 
[39]. The impedance ratio therefore warrants further investigation as a non-invasive 
biomarker in COPD.  
 
Critique of the method 
Although this study cannot establish causation, the association between physical 
inactivity and depletion in muscle bulk in mild disease is strongly suggestive of a 
mechanistic link. The potential role of USRFCSA in detecting longitudinal change and 
response to intervention in COPD remains to be investigated.  
The patients recruited in this cross-sectional study are a combination of those seen in 
hospital outpatients as well as those from the community setting who are not seen in 
secondary care (table 1). Importantly, the patients with mild disease in this study had 
very similar physical activity levels to the GOLD stage I cohort studied by Watz et al 
[14], suggesting that our group is representative of the general COPD population.  
The strong correlation of ultrasound RFCSA with both mid-thigh and rectus femoris CT 
measurements supports the use of rectus femoris as a representation of quadriceps 
bulk and confirms our initial findings in a small cohort of COPD patients [17]. 
Furthermore, inter-observer and inter-occasion agreement for USRFCSA 
measurement in this study were similar to that for other muscle ultrasound imaging 
[40]. The key areas for measurement error in our experience result from operator 
accuracy of probe position in relation to surface anatomy and inaccurate cursor 
outline of the acquired rectus femoris image, both of which may be related to 
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operator training and experience. CT and MR imaging modalities have been shown 
to have an advantage over ultrasound in serial measurements which is likely to relate 
to use of bony landmarks for measurement position in comparison to the use of 
surface anatomy. However, a randomised controlled trial using electrical muscle 
stimulation to reduce muscle wasting in the intensive care unit (ICU) setting has 
shown that ultrasound measurement of the quadriceps has strong potential as a 
bedside imaging modality for identifying serial changes in muscle bulk following 
intervention [41].  
In relation to the objective measurements of activity in this study, both daily step 
count and PAL were used as measures of daily physical activity, although the 
Sensewear armband monitor has been shown to underestimate step count at slow 
walking speeds [22]. This may account for differences in the statistical strength of 
these activity variables when incorporated into the regression analyses. Importantly, 
the study participants showed good compliance with the Sensewear armband in 
keeping with recent data on the wearing time of this device in COPD and healthy 
subjects [42]. 
Conclusion 
In summary, this study has shown that quadriceps wasting identified by USRFCSA 
exists in patients with mild, as well as advanced, COPD. Quadriceps bulk was 
associated with daily physical activity, independent of airflow limitation, in GOLD 
stage I disease. Our data suggest that, rather than being an end-stage phenomenon, 
quadriceps wasting occurs in a substantial minority of COPD patients including those 
with early disease. Ultrasound measurement of rectus femoris cross-sectional area 
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has potential as a physiological biomarker in COPD and the identification of these 
patients may guide early lifestyle and therapeutic interventions. 
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FIGURE LEGENDS 
Figure 1:  Ultrasound assessment of the rectus femoris in the transverse plane 
(RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; VI, 
vastus intermedius). 
Figure 2: Ultrasound rectus femoris cross-sectional area (USRFCSA) versus 
GOLD stage in COPD patients and healthy controls (ANOVA - no 
significant difference between I-IV). Cross bars represent the standard 
error of the mean (SEM). 
Figure 3: Quadriceps maximal voluntary contraction (QMVC) versus GOLD stage 
in COPD and healthy controls (ANOVA - no significant difference 
between GOLD stages, except I and IV; p<0.02). Cross bars represent 
SEM. 
Figure 4:  Daily physical activity (steps) versus GOLD stage in COPD patients and 
healthy controls (ANOVA - significant differences also observed 
between stages 1,3 & 1,4 p<0.0001; 2,3 p=0.002; 2,4 p<0.0001 & 3,4 
p=0.03). Cross bars represent SEM. 
Figure 5: Physical activity level (PAL) versus GOLD stage in COPD subjects and 
healthy controls (ANOVA - significant differences also observed 
between stages 1,3 p=0.0006; 1,4 p=0.0002 & 2,4 p=0.04). Cross bars 
represent SEM. 
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Table 1: Baseline characteristics of COPD and control subjects 
 
  
Controls 
(n=40) 
mean (SD) 
 
COPD 
 I 
(n=38) 
 
COPD 
 II 
(n=45) 
 
COPD 
 III 
(n=41) 
 
COPD 
 IV 
(n=37) 
 
p 
value 
 
Age (years) 
 
65 (8) 
 
67 (9) 
 
67 (9) 
 
67 (9) 
 
63 (8) 
 
0.17 
 
Gender (M/F) 
 
20/20 
 
19/19 
 
22/23 
 
22/19 
 
25/12 
 
0.45 
 
BMI      
(kg/m2) 
 
25.9  
(3.6) 
 
26.5  
(4.8) 
 
26.6  
(5.9) 
 
25.2  
(4.5) 
 
22.4  
(3.8) 
 
0.0006 
 
FFMI    
(kg/m2) 
 
17.8  
(2.1) 
 
17.9  
(2) 
 
17.7  
(2.7) 
 
17.6  
(2.2) 
 
16.2  
(1.9) 
 
0.004 
 
Smoking    
(pack years) 
 
9.1  
(14.3) 
 
28.1 
(22.2) 
 
42   
(29.2) 
 
50   
(26.2) 
 
55.5 
(29.3) 
 
<0.0001 
 
Current 
smokers (%) 
 
- 
 
11 
 
 
29 
 
27 
 
14 
 
 
 
0.09 
Outpatients 
(%) 
- 47 
 
60 66 89 0.001 
 
Long-acting 
beta agonist 
(%) 
   
 
- 
 
58 
 
80 
 
85 
 
100 
 
<0.0001 
Long-acting 
anticholinergic 
(%) 
 
- 
 
42 
 
71 
 
83 
 
97 
 
<0.0001 
 
Inhaled 
corticosteroid 
(%) 
 
- 58 78 83 100 <0.0001 
Oral 
corticosteroid  
(% ≥5mg/day) 
- 0 0 0 8 0.02 
 
FEV1 %    
pred 
 
103.1 
(11.7) 
 
90.8  
(8.8) 
 
63.2  
(8.8) 
 
39.4  
(5.5) 
 
24  
(3.8) 
 
<0.0001 
 
TLco%     
pred 
 
89.3  
(17.1) 
 
67.5 
(17.8) 
 
58.1 
(14.7) 
 
39.9 
(13.9) 
 
26.6  
(9) 
 
<0.0001 
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RV%TLC  
ratio 
 
34  
(4.6) 
 
40.6  
(6.6) 
 
46.6  
(8) 
 
57.9  
(7.5) 
 
64.7  
(6.9) 
 
<0.0001 
 
IC 
(litres) 
 
2.8 
(0.7) 
 
2.7 
(0.8) 
 
2.3 
(0.8) 
 
1.9 
(0.6) 
 
1.8 
(0.4) 
 
<0.0001 
 
PaO2 
(kPa) 
 
11.2  
(1.1) 
 
10.6  
(1.5) 
 
10.2  
(1.2) 
 
9.1  
(1.2) 
 
9.1  
(1.3) 
 
<0.0001 
 
PaCO2 
(kPa) 
 
5  
(0.6) 
 
4.7  
(0.5) 
 
5  
(0.4) 
 
5.1  
(0.5) 
 
5.4  
(0.6) 
 
<0.0001 
 
MRC score 
(1-5) 
 
1.1  
(0.3) 
 
1.8 
(0.4) 
 
2.5  
(0.9) 
 
3.1 
(0.9) 
 
3.6  
(0.9) 
 
<0.0001 
 
SGRQ 
(Symptoms) 
 
- 
 
29.4 
(24.8) 
 
49.6 
(22.8) 
 
50 
(23.7) 
 
61.6 
(19.1) 
 
<0.0001 
 
SGRQ 
(Activity) 
 
 
- 
 
34.7 
(25) 
 
58.1 
(23.9) 
 
 
70.1 
(19.4) 
 
84.5 
(11.5) 
 
<0.0001 
SGRQ 
(Impacts) 
- 15.5 
(15.1) 
29.9 
(17.4) 
33.8 
(17.4) 
48.4 
(18.1) 
<0.0001 
 
SGRQ  
(Total) 
 
- 
 
23.1 
(16.8) 
 
41.1 
(17.9) 
 
 
47.6 
(16.4) 
 
 
61.5 
(13.8) 
 
 
<0.0001 
 
 
Abbreviations: BMI - body mass index; FFMI – fat free mass index; FEV1 - forced 
expiratory volume in 1 second; TLco – carbon monoxide diffusing capacity; RV – 
residual volume; TLC – total lung capacity; IC – inspiratory capacity; PaO2 - arterial 
partial pressure of oxygen; PaCO2 - arterial partial pressure of carbon dioxide; SGRQ 
– St George’s respiratory questionnaire; Outpatients – defined as any previous 
hospital clinic attendance.
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Table 2: Quadriceps and physical activity measurements in COPD and control 
subjects 
  
Controls 
mean 
(SD) 
 
COPD 
I 
 
COPD 
II 
 
COPD 
III 
 
COPD 
IV 
 
P 
value 
 
USRFCSA 
(mm2) 
 
640 
(136) 
 
530 
(116) 
 
511 
(135) 
 
504 
(122) 
 
509 
(122) 
 
<0.0001 
 
QMVC 
(kg) 
 
 
34.3     
(8.8) 
 
29.6           
(7.2) 
 
27.9            
(7.3) 
 
27.3        
(8.8) 
 
25.3        
(6.8) 
 
<0.0001 
Step count 
 
11735 
(4399) 
7960  
(3430) 
6606   
(3328) 
4010 
(2316) 
2219 
(1157) 
<0.0001 
 
Physical 
Activity 
Level 
 
1.69 
(0.25) 
 
1.56 
(0.16) 
 
1.47 
(0.16) 
 
1.4 
(0.12) 
 
1.38 
(0.19) 
 
<0.0001 
 
 Armband  
wearing 
time 
 (hours/day) 
 
 
23.57  
(0.28) 
 
 
23.60 
(0.26) 
 
 
23.64 
 (0.37) 
 
 
23.57 
 (0.52) 
 
 
23.61 
 (0.39) 
 
 
0.95 
 
Z200/Z5 
Impedance 
ratio 
 
 
0.789 
(0.03) 
 
0.791 
(0.03) 
 
0.806 
(0.03) 
 
0.816 
(0.03) 
 
0.814 
(0.03) 
 
0.0002 
 
Abbreviations: USRFCSA – ultrasound rectus femoris cross-sectional area; QMVC – 
quadriceps maximal voluntary contraction.  
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Figure 1: Ultrasound assessment of the rectus femoris in the transverse plane (RF, rectus femoris; VL, 
vastus lateralis; VM, vastus medialis; VI, vastus intermedius).  
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Figure 2: Ultrasound rectus femoris cross-sectional area (USRFCSA) versus GOLD stage in COPD patients and 
healthy controls (ANOVA - no significant difference between I-IV). Cross bars represent the standard error 
of the mean (SEM).  
177x172mm (300 x 300 DPI)  
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Figure 3: Quadriceps maximal voluntary contraction (QMVC) versus GOLD stage in COPD and healthy 
controls (ANOVA - no significant difference between GOLD stages, except I and IV; p<0.02). Cross bars 
represent SEM.  
177x174mm (300 x 300 DPI)  
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Figure 4: Daily physical activity (steps) versus GOLD stage in COPD patients and healthy controls (ANOVA - 
significant differences also observed between stages 1,3 & 1,4 p<0.0001; 2,3 p=0.002; 2,4 p<0.0001 & 3,4 
p=0.03). Cross bars represent SEM.  
177x170mm (300 x 300 DPI)  
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Figure 5: Physical activity level (PAL) versus GOLD stage in COPD subjects and healthy controls (ANOVA - 
significant differences also observed between stages 1,3 p=0.0006; 1,4 p=0.0002 & 2,4 p=0.04). Cross 
bars represent SEM.  
177x175mm (300 x 300 DPI)  
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Quadriceps wasting and physical inactivity in patients with COPD 
 
ONLINE SUPPLEMENT 
Dinesh Shrikrishna, Mehul Patel, Rebecca J Tanner, John M Seymour, Bronwen A 
Connolly, Zudin A Puthucheary, Simon LF Walsh, Susannah A Bloch, Paul S Sidhu, 
Nicholas Hart, Paul R Kemp, John Moxham, Michael I Polkey, Nicholas S Hopkinson 
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METHODS  
Quadriceps maximal voluntary contraction (QMVC) 
The subject sat on a modified chair with their knee fixed at 90 degrees. An 
inextensible strap connected the ankle of their dominant leg to a strain gauge. The 
signal from the strain gauge was amplified and passed to a computer running 
CHART software (Labchart version 7.1, PowerLab Analogue-Digital Converter, AD 
instruments, Oxfordshire, UK). The subject performed at least 3 sustained maximal 
isometric quadriceps contractions of between 5 and 10 seconds duration. Consistent 
traces within 5% of maximum were obtained. A gap of approximately 30 seconds 
was given between each contraction to allow time to recover. Vigorous 
encouragement was given and the force generated was visible online using the 
CHART software. The QMVC was taken as highest tension sustained for 1 second.  
Fat free mass measurement using bioelectrical impedance 
This technique uses the electrical impedance of body tissues to determine an 
estimate of total body water, as electricity is conducted by dissolved ions. A two-
compartment model is used which assumes that adipose tissue contains no water 
and that the FFM is of a particular percentage water. Single frequency, 50kHz, 
bioelectrical impedance values are incorporated into regression equations which 
include height, weight and gender to calculate fat free mass (FFM). 
 Mid-thigh Computed Tomography (CT) Cross-sectional area 
CT was performed on a 64-slice CT scanner (Siemens SOMATOM Sensation 64, 
Erlangen, Germany) with the patient in a supine position. A single section of the mid-
thigh at a predefined level was obtained using the following acquisition parameters: 
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50mAs, 120kVp. The protocol was modified to deliver a reduced amount of radiation 
per scan. Images were viewed and CT cross-sectional areas calculated using Digital 
Imaging Communications in Medicine viewing software (DicomWorks, version 
1.3;http://dicom.online.fr) at standard window settings for visualisation of soft tissues 
(centre 40 HU, window width 380 HU).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 35 of 123 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4 
 
RESULTS 
Ultrasound rectus femoris pennation angle and measurement distance 
Using values of rectus femoris pennation angle (RFPA), the angle at which these 
muscle fibres insert into the muscle aponeurosis, to derive ultrasound rectus femoris 
physiological cross-sectional area (USRFPCSA), the relationship between USRFPCSA 
and quadriceps strength (QMVC) was compared to that between anatomical 
USRFCSA alone and QMVC in a group of 31 healthy adults, 9 of whom were males, 
median (IQR) age 31 (24.5-37) years.  USRFCSA and USRFPCSA were measured at 
both three fifths and two thirds distance from anterior superior iliac spine to the 
superior patellar border.  Correlations were determined using Pearson’s correlation 
coefficient and revealed no differences in relationship between anatomical (USRFCSA) 
and physiological (USRFPCSA) cross-sectional areas measured at either distance, and 
quadriceps strength, suggesting that pennation angle added no further value to the 
relationship between cross-sectional area and strength (online table 4). 
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FIGURE LEGEND 
Online Figure 1:  Quadriceps strength (QMVC) versus ultrasound rectus femoris 
   cross-sectional area (USRFCSA) in COPD patients (Pearson  
   correlation; r=0.6, p<0.0001) 
Online Figure 2:  Quadriceps strength (QMVC) versus Impedance ratio in COPD 
   patients (Pearson correlation; r=−0.54, p<0.0001). 
Online Figure 3: Ultrasound rectus femoris cross-sectional area (USRFCSA) in 
 COPD patients and healthy controls separated by gender - 
 males (A) and females (B); (ANOVA - no significant difference 
 between stages I-IV). Cross bars represent SEM. 
Online Figure 4:   Bland-Altman analysis comparing the rectus femoris cross-
 sectional area (RFCSA) measured by ultrasound on two 
 separate occasions (n=21). Mean (SD) bias - 0.06 (0.21) cm2 : 
 coefficient of repeatability 0.41cm2, Dotted line represents 95% 
 limits of agreement -0.47 to +0.36 cm2 , index of reliability 0.97. 
 Similar analysis was conducted for inter-observer variability 
 (n=10): mean (SD) bias 0.11 (0.29) cm2 : coefficient of 
 repeatability 0.57cm2, 95% limits of agreement -0.46 to +0.68 
 cm2, index of reliability 0.97. 
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TABLES 
Online Table 1: Univariate correlates of USRFCSA in all COPD subjects 
    USRFCSA (r) p 
Age −0.20 0.01 
Gender   0.48 <0.0001 
FFMI   0.49 <0.0001 
FEV1 % pred   0.08 0.32 
TLco% pred   0.26 0.001 
RV/TLC ratio −0.22 0.006 
IC   0.44 <0.0001 
QMVC   0.60 <0.0001 
Impedance ratio −0.53 <0.0001 
PAL   0.20 <0.05 
Steps    0.30 0.002 
   
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - 
ultrasound rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 
second; RV – residual volume; TLC – total lung capacity; IC – inspiratory capacity; 
TLco – carbon monoxide diffusing capacity; FFMI - fat free mass index; PAL – 
physical activity level;  r and p values derived from Pearson’s correlation coefficient.  
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Online Table 2: Univariate correlates of USRFCSA in stage I COPD subjects 
    USRFCSA (r)  p 
Age −0.33 0.04 
Gender   0.50   0.001 
FFMI   0.43   0.007 
FEV1 % pred   0.07 0.70 
TLco% pred   0.38 0.03 
RV/TLC ratio −0.42 0.01 
IC   0.41 0.02 
QMVC   0.63   <0.0001 
Impedance ratio −0.64   <0.0001 
PAL   0.70   <0.0001 
Steps    0.53   0.002 
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - 
ultrasound rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 
second; RV – residual volume; TLC – total lung capacity; IC – inspiratory capacity; 
TLco – carbon monoxide diffusing capacity; FFMI - fat free mass index; PAL – 
physical activity level. r and p values derived from Pearson’s correlation coefficient.    
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Online Table 3: Univariate correlates of physical activity in stages II-IV COPD 
  Steps (r) p  PAL (r) p 
Age  −0.12 0.25 −0.08  0.46 
Gender   0.18 0.10   0.14  0.18 
FFMI   0.19 0.07   0.10  0.40 
USRFCSA   0.24 0.02   0.05  0.70 
FEV1% pred   0.57   <0.0001   0.21 <0.05 
TLco% pred   0.54   <0.0001   0.07   0.50 
RV/TLC ratio −0.53   <0.0001 −0.23   0.03 
IC   0.27 0.01   0.01   0.92 
QMVC   0.22 0.04   0.02   0.82 
Impedance ratio −0.27 0.01 −0.12   0.30 
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - 
ultrasound rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 
second; RV – residual volume; TLC – total lung capacity; IC – inspiratory capacity; 
TLco – carbon monoxide diffusing capacity; FFMI - fat free mass index; PAL – 
physical activity level. r and p values derived from Pearson’s correlation coefficient. 
Using regression analysis, RV/TLC ratio was retained over FEV1% predicted as the 
only independent predictor of physical activity level in stage II-IV COPD patients 
(p=0.03). FEV1% predicted and TLco% predicted were independent predictors of 
step count (p<0.0001). 
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Online Table 4:  Relationship between rectus femoris anatomical cross-sectional 
area (RFCSA) and rectus femoris physiological cross-sectional area (RFPCSA) with 
quadriceps strength 
 r p 
3/5 USRFCSA + QMVC 0.7 0.001 
3/5 USRFPCSA + QMVC 0.7 0.001 
2/3 USRFCSA + QMVC 0.6 0.002 
2/3 USRFPCSA + QMVC 0.6 0.002 
 
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - 
ultrasound rectus femoris cross-sectional area; USRFPCSA - rectus femoris 
physiological cross sectional area; 3/5 - measurements performed at three fifths 
distance between anterior superior iliac spine and superior patellar border; 2/3 - 
measurements performed at two thirds distance.  r and p values derived from 
Pearson’s correlation coefficient.    
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Online Table 5:  Univariate correlates of the impedance ratio in COPD patients.  
  r p 
Age   0.37 <0.0001 
Gender   0.34 <0.0001 
QMVC −0.54 <0.0001 
USRFCSA −0.53 <0.0001 
FEV1% pred −0.32   0.0001 
FFMI −0.48 <0.0001 
Steps −0.35   0.0001 
PAL −0.27 0.003 
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - 
ultrasound rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 
second; FFMI - fat free mass index; PAL – physical activity level.  r and p values 
derived from Pearson’s correlation coefficient. 
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Online Figure 1: Quadriceps strength (QMVC) versus ultrasound rectus femoris cross-sectional area 
(USRFCSA) in COPD patients (Pearson correlation; r=0.6, p<0.0001)  
177x123mm (300 x 300 DPI)  
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Online Figure 2: Quadriceps strength (QMVC) versus Impedance ratio in COPD patients (Pearson correlation; 
r=-0.54, p<0.0001).  
177x123mm (300 x 300 DPI)  
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Online Figure 3: Ultrasound rectus femoris cross-sectional area (USRFCSA) in COPD patients and healthy 
controls separated by gender - males (A) and females (B); (ANOVA - no significant difference between 
stages I-IV). Cross bars represent SEM.  
253x126mm (150 x 150 DPI)  
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Online Figure 4: Bland-Altman analysis comparing the rectus femoris cross-sectional area (RFCSA) measured 
by ultrasound on two separate occasions (n=21). Mean (SD) bias - 0.06 (0.21) cm2:coefficient of 
repeatability 0.41cm2, Dotted line represents 95% limits of agreement -0.47 to +0.36 cm2 , index of 
reliability 0.97. Similar analysis was conducted for inter-observer variability(n=10): mean (SD) bias 0.11 
(0.29) cm2 : coefficient of repeatability 0.57cm2, 95% limits of agreement -0.46 to +0.68 cm2, index of 
reliability 0.97.  
178x115mm (300 x 300 DPI)  
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